
Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
Merck KGaA has swooped in and bought US-based Sigma-Aldrich in a deal worth $17 billion (€13.1 billion). The acquisition will …

Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …
The subsidiary of Merck KGaA named EMD Serono has announced several appointments to its leadership team. The appointments include: Allene …
Merck KGaA has outlined its plan to make €300 million in savings from its Serono drugs unit, with over half …

